Ropes & Gray Represents Pfizer in $2.26 Billion Acquisition of Trillium Therapeutics
A Ropes & Gray team represented Pfizer Inc. in its acquisition of Trillium Therapeutics Inc., announced August 23, 2021. The companies have entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. Under the terms of the agreement, Pfizer will acquire all outstanding shares of Trillium not already owned by Pfizer for an implied equity value of $2.26 billion, or $18.50 per share, in cash. This represents a 118% premium to the 60-day weighted average price for Trillium.
Read the press release here.
The Ropes & Gray team representing Pfizer was led by strategic transactions partner Emily Oldshue, and included strategic transactions partners Paul Kinsella and Amanda Austin, tax partner David Saltzman, executive compensation partner Renata Ferrari, and antitrust partners Mike McFalls and Ruchit Patel and strategic transactions associates Jeff Bashara and Joseph DiCarlo.